LINEAGE CELL THERAPEUTICS IN (LCTX)

US53566P1093 - Common Stock

0.558  +0.06 (+11.16%)

After market: 0.552 -0.01 (-1.08%)

Buy % Consensus

81

ChartMill assigns a Buy % Consensus number of 81% to LCTX. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 4.66. This target is 735.63% above the current price.
LCTX was analyzed by 14 analysts. The buy percentage consensus is at 81. So analysts seem to be very confident about LCTX.
In the previous month the buy percentage consensus was at a similar level.
LCTX was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.

Price Target & Forecast

Price Low Median Mean High 0.562.025.104.667.35 - 262.01% 813.98% 735.63% 1,217.20%
Up and Down Grades
Date Firm Action Rating
2024-12-04 HC Wainwright & Co. Maintains Buy -> Buy
2024-11-20 D. Boral Capital Maintains Buy -> Buy
2024-11-18 D. Boral Capital Initiate Buy
2024-08-20 Craig-Hallum Initiate Buy
2024-05-06 HC Wainwright & Co. Reiterate Buy -> Buy
2024-03-08 HC Wainwright & Co. Reiterate Buy -> Buy
2024-02-13 HC Wainwright & Co. Reiterate Buy -> Buy
2024-02-05 Cantor Fitzgerald Reiterate Overweight -> Overweight
2023-08-11 HC Wainwright & Co. Reiterate Buy -> Buy
2023-07-25 Cantor Fitzgerald Reiterate Overweight -> Overweight
2023-07-24 HC Wainwright & Co. Reiterate Buy -> Buy
2023-05-12 HC Wainwright & Co. Reiterate Buy -> Buy
2023-04-26 HC Wainwright & Co. Reiterate Buy
2023-03-10 HC Wainwright & Co. Reiterate Buy
2022-11-02 Baird Initiate Outperform
2022-06-14 B. Riley Securities Initiate Buy
2021-08-19 Noble Capital Markets Initiate Outperform
2021-03-31 Cantor Fitzgerald Initiate Overweight